Cardoso, IsabelMelo, MafaldaBrás, PedroViegas, José MiguelAlmeida, InêsNunes, SofiaCustódio, InêsTrigo, ConceiçãoLaranjo, SérgioLaranjo, SergioGraça, RafaelCruz Ferreira, RuiOliveira, MárioMartinsAguiar Rosa, SílviaAntunes, Diana2025-07-282025-07-302025-050870-2551PURE: 115300760PURE UUID: 28951875-d62f-421c-bab8-f04cfa4526acScopus: 105003257334Scopus: 105002667760http://hdl.handle.net/10362/185649Publisher Copyright: © 2025 Sociedade Portuguesa de CardiologiaCardiomyopathies may present as a manifestation of various inherited syndromes. Recognizing the rarity and diagnostic challenges of syndromic and metabolic cardiomyopathies is crucial, as their identification holds significant implications for targeted treatment and enables the use of specific risk stratification tools. Genetics has assumed a pivotal role in clarifying the pathophysiology of cardiomyopathies, facilitating molecular diagnosis, and enabling effective family screening. The advent of next-generation sequencing has revolutionized genetic testing, enabling cost-effective, high-throughput analyses, facilitating the diagnosis of these rare conditions, and allowing the provision of specific management and therapeutics.9655421engGeneticsGenotypeMetabolic cardiomyopathiesRisk stratificationSyndromic cardiomyopathiesCardiology and Cardiovascular Medicinereview10.1016/j.repc.2024.11.016https://www.scopus.com/pages/publications/105002667760